Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms-Reference-Cited by-同舟云学术

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Published:2018-01-03 Issue:11 Volume:9 Page:9714-9727
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Montalban-Bravo Guillermo¹,Takahashi Koichi¹²,Patel Keyur³,Wang Feng²,Xingzhi Song⁴,Nogueras Graciela M.⁵,Huang Xuelin⁵,Pierola Ana Alfonso¹,Jabbour Elias¹,Colla Simona¹,Gañan-Gomez Irene¹,Borthakur Gautham¹,Daver Naval¹,Estrov Zeev¹,Kadia Tapan¹,Pemmaraju Naveen¹,Ravandi Farhad¹,Bueso-Ramos Carlos³,Chamseddine Ali¹,Konopleva Marina¹,Zhang Jianhua⁴,Kantarjian Hagop¹,Futreal Andrew²,Garcia-Manero Guillermo¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

2. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4. Applied Cancer Science Institute, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

5. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in the management of higher-risk myelodysplastic syndromes: future prospects;Leukemia & Lymphoma;2024-05-07

2. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms;Modern Pathology;2024-02

3. Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes;Therapeutic Advances in Hematology;2024-01

4. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study;Journal of Clinical Oncology;2023-05-20

5. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms;Blood Cancer Journal;2023-04-11